title: Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits.
abstract: OBJECTIVE
  To assess the effect of high doses of valacyclovir (VCV) on HSV-1 DNA shedding into tears of latently infected rabbits.
  
  
  METHODS
  Three oral doses of VCV were tested. Corneas were inoculated with HSV-1, and latent infection was allowed to establish. Starting on postinoculation (PI) day 28, tear swabs were collected once daily for 6 consecutive days before treatment. The rabbits were placed in five balanced groups: group 1 had no treatment, group 2 received placebo, group 3 received 7 mg/kg VCV, group 4 received 70 mg/kg, and group 5 received 140 mg/kg. The treatment was administered by oral gavage twice daily, starting on PI day 36 and continuing for 14 days. The ocular swabs were collected beginning on PI day 40 and continuing for 10 days.
  
  
  RESULTS
  The mean copy number of HSV-1 DNA before treatment was 370+/-70, 569+/-273, 368+/-86, 408+/-108, and 396+/-91, and the mean HSV-1 DNA copy number after treatment was 232+/-183, 564+/-186, 518+/-122, 67+/-63, and 13+/-7 in groups 1 to 5, respectively.
  
  
  CONCLUSIONS
  There was no observable toxicity in any group. The 70- and 140-mg/kg doses of VCV significantly reduced the HSV-1 DNA copy number, compared with that of the other three groups. A daily dose of 500 mg (approximately 7 mg/kg) VCV in healthy human volunteers did not suppress HSV-1 DNA shedding in tears and saliva. Thus, higher doses of VCV may be necessary to reduce asymptomatic shedding in healthy human subjects.
authors.affiliation: Department of Ophthalmology, Neuroscience Center of Excellence, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
authors.forename: Manish
authors.initials: M
authors.lastname: Kumar
authors.forename: Herbert E
authors.initials: HE
authors.lastname: Kaufman
authors.forename: Christian
authors.initials: C
authors.lastname: Clement
authors.forename: Partha S
authors.initials: PS
authors.lastname: Bhattacharjee
authors.forename: Tashfin S
authors.initials: TS
authors.lastname: Huq
authors.forename: Emily D
authors.initials: ED
authors.lastname: Varnell
authors.forename: Hilary W
authors.initials: HW
authors.lastname: Thompson
authors.forename: James M
authors.initials: JM
authors.lastname: Hill
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D018628:Gene Dosage; D006561:Herpes Simplex / Q000188:drug therapy / Q000635:transmission / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D011817:Rabbits; D013666:Tears / Q000187:drug effects / Q000821:virology*; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017735:Virus Latency
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):43-50
references.pmid: 17703961
references.citation: Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41
references.pmid: 12878501
references.citation: Sex Transm Dis. 2008 Apr;35(4):383-6
references.pmid: 18362859
references.citation: Schizophr Res. 2009 Feb;107(2-3):147-9
references.pmid: 19008077
references.citation: J Virol. 2008 Aug;82(16):8230-4
references.pmid: 18550674
references.citation: Invest Ophthalmol Vis Sci. 2005 Jan;46(1):241-7
references.pmid: 15623779
references.citation: J Infect Dis. 2008 Dec 15;198(12):1804-8
references.pmid: 18928378
references.citation: Trans Am Ophthalmol Soc. 2000;98:285-303
references.pmid: 11190029
references.citation: Antimicrob Agents Chemother. 1995 Dec;39(12):2759-64
references.pmid: 8593015
references.citation: Drugs. 2000 Apr;59(4):839-63
references.pmid: 10804039
references.citation: J Infect Dis. 2004 Oct 15;190(8):1374-81
references.pmid: 15378428
references.citation: Eur J Neurol. 2009 Apr;16(4):457-60
references.pmid: 19187258
references.citation: J Cutan Med Surg. 2003 Sep-Oct;7(5):372-81
references.pmid: 14505192
references.citation: J Infect Dis. 2008 May 1;197(9):1289-95
references.pmid: 18422441
references.citation: N Engl J Med. 2004 Jan 1;350(1):11-20
references.pmid: 14702423
references.citation: Semin Ophthalmol. 2008 Jul-Aug;23(4):249-73
references.pmid: 18584563
references.citation: J Virol. 2009 Nov;83(22):11857-61
references.pmid: 19740997
references.citation: J Antimicrob Chemother. 2001 Jun;47(6):855-61
references.pmid: 11389118
references.citation: Cornea. 1999 Nov;18(6):693-9
references.pmid: 10571301
references.citation: Arch Neurol. 2006 Jul;63(7):940-2
references.pmid: 16682531
references.citation: Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5601-8
references.pmid: 19608530